Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Biological: CP-751,871
Biological: CP-751,871, moxifloxacin, saline

First Posted Date: 2009-06-23

Last Posted Date: 2013-05-07

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT00926263

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Drug Interaction Study Between Rifabutin And Lersivirine (UK-453,061)

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Lersivirine
Drug: Rifabutin

First Posted Date: 2009-06-22

Last Posted Date: 2010-09-21

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT00925535

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis

Phase 3

Completed

Conditions: ATTR-PN

Interventions: Drug: Tafamidis

First Posted Date: 2009-06-19

Last Posted Date: 2021-07-29

Lead Sponsor: Pfizer

Target Recruit Count: 93

Registration Number: NCT00925002

Locations: 🇵🇹
Unidade Clinica de Paramiloidose Centro Hospitalar do Porto, EPE - Hospital Geral de Santo António, Porto, Portugal
🇸🇪
FAP-Teamet Familjar Amyloidos, Umea, Sweden
🇩🇪
Universitatsklinikum Muenster, Muenster, Germany

and more 6 locations

Long Term Safety Study of Tanezumab in Chronic Low Back Pain

Phase 2

Terminated

Conditions: Low Back Pain

Interventions: Biological: Tanezumab 20 mg
Biological: Tanezumab 10 mg

First Posted Date: 2009-06-19

Last Posted Date: 2021-04-21

Lead Sponsor: Pfizer

Target Recruit Count: 849

Registration Number: NCT00924664

Locations: 🇺🇸
Wake Internal Medicine Consultants, Inc., Raleigh, North Carolina, United States
🇺🇸
Comprehensive Clinical Research, Berlin, New Jersey, United States
🇺🇸
Diagnostic Imaging Centers, Overland Park, Kansas, United States

and more 143 locations

Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Dalteparin

First Posted Date: 2009-06-17

Last Posted Date: 2012-01-23

Lead Sponsor: Pfizer

Target Recruit Count: 618

Registration Number: NCT00922766

Locations: 🇮🇳
Pfizer Investigational Site, Kolkata, West Bengal, India

A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder

Phase 2

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Drug: PD 0332334
Drug: placebo
Drug: Alprazolam extended release

First Posted Date: 2009-06-16

Last Posted Date: 2010-02-19

Lead Sponsor: Pfizer

Target Recruit Count: 222

Registration Number: NCT00921063

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Phase 3

Completed

Conditions: Kidney Neoplasms

Interventions: Drug: Axitinib (AG-013736)
Drug: Sorafenib

First Posted Date: 2009-06-15

Last Posted Date: 2022-05-06

Lead Sponsor: Pfizer

Target Recruit Count: 492

Registration Number: NCT00920816

Locations: 🇺🇸
US Oncology West Region, Henderson, Nevada, United States
🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇺🇸
Hematology-Oncology Associates of Northern NJ, PA, Parsippany, New Jersey, United States

and more 93 locations

Axitinib Pharmacokinetics in Chinese Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: AG-013736 (axitinib)

First Posted Date: 2009-06-12

Last Posted Date: 2009-09-21

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT00919204

Locations: 🇨🇳
Pfizer Investigational Site, Beijng, China

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease

Phase 3

Completed

Conditions: Pneumococcal Conjugate Vaccine

Interventions: Biological: 13-valent Pneumoccocal Conjugate Vaccine

First Posted Date: 2009-06-11

Last Posted Date: 2014-04-21

Lead Sponsor: Pfizer

Target Recruit Count: 158

Registration Number: NCT00918580

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: filibuvir + Oral Contraceptives

First Posted Date: 2009-06-11

Last Posted Date: 2011-04-19

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT00918476

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy